Alert

Recommended Alerts

Sign Up For Alerts

Interim Final Rule Implements Controversial Surprise Billing Arbitration Provisions

On Thursday, October 7, the Biden Administration published in the Federal Register its second interim final rule implementing the “No Surprises Act,” which became law on December 27, 2020 as part of the FY 2021 Consolidated Appropriations Act.

Read More

Food and Drug Administration Releases Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens

Practices: Health Care, Life Sciences Industries: Biotechnology & Pharmaceuticals

Printer-Friendly Version

Cookie Settings